Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Dissecting the heterogeneity of IGHV-mutated CLL: An eric study.

Thomas Chatzikonstantinou, Andreas Agathangelidis, Persefoni Talimtzi, Stamatia Laidou, Eva Minga, Athanasios Roussos, Maria Angelopoulou, Miguel Arguello De Tomas, Darko Antic, Fanny Baran-Marszak, Csaba Bödör, Francesc Bosch Albareda, Mark Catherwood, Sophia Chatzileontiadou, Caterina Chessa, Marta Coscia, Marta Crespo, Antonio Cuneo, Zadie Davis, Maria Dimou, Michael Doubek, Maria Efstathopoulou, Blanca Espinet, Gianluca Gaidano, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Thalia Karamanli, Eliana Konstantinou, Ioannis Kotsianidis, Andreas Epameinondas Koumpis, Tamas Laszlo, Vincent Levy, Alexandros Machairas, Francesca Martini, Riccardo Moia, Samir Mouhssine, Ana Muntanola Prat, Roberta Murru, Eugenia Mpalaoura, Gerassimos Pangalis, Maria Papaioannou, Sarka Pavlova, Karla Plevova, Sarka Pospisilova, Anna Puiggros, Lata Rani, Gian Matteo Rigolin, Ilaria Romano, Davide Rossi, Angel Serna, Martin Simkovic, Lukas Smolej, Niki Stavrogianni, Kristina Tomic Vujovic, Livio Trentin, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Lydia Scarfo, Anastasia Chatzidimitriou, Paolo Ghia, Kostas Stamatopoulos

Blood (2025) 146 (Supplement 1): 2120.

https://doi.org/10.1182/blood-2025-2120

Published: 2025

Journal Articles

Targeting a novel surface antigen, ryk, with the antibody-drug conjugate, slv-404, is effective in richter transformation patient-derived xenografts

Matilde Micillo, Beatrice Pirajno, Maria Chiara Montalbano, Giulia Giuffrè, Francesco Vallone, Giulia Omezzolli, Amelia Fascì, Nahal Nabelsi, Victor Navarro-Tableros, Elisabetta Bolli, Samir Mouhssine, Riccardo Moia, Candida Vitale, Gianluca Gaidano, Brian Lannutti, Katti Jessen, Tiziana Vaisitti, Silvia Deaglio

Blood (2025) 146 (Supplement 1): 7063.

https://doi.org/10.1182/blood-2025-7063

Published: 2025

Journal Articles

Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 5657.

https://doi.org/10.1182/blood-2025-5657

Published: 2025

Journal Articles

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Blood (2025) 146 (Supplement 1): 7427.

https://doi.org/10.1182/blood-2025-7427

Published: 2025

Journal Articles

Brentuximab vedotin (Bv)+AVD efficacy is influenced by interim PET, age, ECOG performance status and CIRS-g in previously untreated patients with stage IV classical Hodgkin lymphoma: An Italian real-life multicentric study

Blood (2025) 146 (Supplement 1): 5402.

https://doi.org/10.1182/blood-2025-5402

Published: 2025

Journal Articles

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfo, Persefoni Talimtzi, Maria Angelopoulou, Tomas Arpas, Laura Ballotta, Leonidas Benetatos, Ana Margarida Bertolo, Horia Bumbea, Maurizio Cavallari, Anastasia Chatzidimitriou, Dominik Chraniuk, Anna Christoforidou, Francesca Cibien, Antonio Cuneo, Maria Ilaria del Principe, Marina Deodato, Enrico Derenzini, Michael Doubek, Fabiana Esposito, Lucia Farina, Gianmarco Favrin, Isacco Ferrarini, Annamaria Frustaci, Andrea Galitzia, Massimo Gentile, Iulia Roxana Iancu, Vanessa Innao, krzysztof jamroziak, Elzbieta Kalicinska, Maria Kislova, Ioannis Kyriakou, Luca Laurenti, Enrico Lista, Javier Loscertales, Alexandros Machairas, Giorgia Marcato, Francesca Martini, Nilla Maschio, Eva Minga, Riccardo Moia, Roberta Murru, Maura Nicolosi, Jacopo Olivieri, Carolina Pavlovsky, Miguel Pavlovsky, Sara Pepe, Ernesto Perez Persona, Giuseppe Petruzzellis, Gian Matteo Rigolin, Alessandro Sanna, Marina Siakantaris, Paolo Sportoletti, Oana Stanca, Niki Stavrogianni, Tamar Tadmor, Annamaria Tomasso, Marzia Varettoni, Theodoros Vassilakopoulos, Eva Gimeno Vazquez, Candida Vitale, Mohamed Yassin, Mihnea Zdrenghea, Klaudia Zielonka, Livio Trentin, Kostas Stamatopoulos, Paolo Ghia

Blood (2025) 146 (Supplement 1): 6287.

https://doi.org/10.1182/blood-2025-6287

Published: 2025

Journal Articles

Chronic obstructive pulmonary disease and prior pneumonia as predictors of infectious risk in chronic lymphocytic leukemia patients receiving acalabrutinib or zanubrutinib: A seifem multicentre Study.

Blood (2025) 146 (Supplement 1): 5678.

https://doi.org/10.1182/blood-2025-5678

Published: 2025

Journal Articles

Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.

Blood (2025) 146 (Supplement 1): 5671.

https://doi.org/10.1182/blood-2025-5671

Published: 2025

Journal Articles

Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by eric.

Thomas Chatzikonstantinou, Sevasti Konstantinou, Persefoni Talimtzi, Eva Minga, Maria Angelopoulou, Francesco Angotzi, Marcello Bradaschia, Sophia Chatzileontiadou, Caterina Chessa, Marta Crespo, Maria Dimou, Alessandro Gozzetti, Ritu Gupta, Eliana Konstantinou, Andreas Epameinondas Koumpis, Alexandros Machairas, Francesca Martini, Riccardo Moia, Samir Mouhssine, Roberta Murru, Leila Perobelli, Lata Rani, Ilaria Romano, Gian Matteo Rigolin, Angel Serna, Andrea Visentin, Candida Vitale, George Vrachiolias, Celso Arrais-Rodrigues, Rodrigo Santucci da Silva, Carlos Chiattone, Francesc Bosch Albareda, Anastasia Chatzidimitriou, Marta Coscia, Antonio Cuneo, Gianluca Gaidano, Eleftheria Hatzimichael, Yair Herishanu, Ioannis Kotsianidis, Panagiotis Panagiotidis, Maria Papaioannou, Davide Rossi, Niki Stavrogianni, Livio Trentin, Theodoros Vassilakopoulos, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2025) 146 (Supplement 1): 5665.

https://doi.org/10.1182/blood-2025-5665

Published: 2025

Journal Articles

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.

Thomas Chatzikonstantinou, Persefoni Talimtzi, Eva Minga, Maria Angelopoulou, Miguel Arguello De Tomas, Darko Antic, Celso Arrais-Rodrigues, Francesc Bosch Albareda, Marcello Bradaschia, Alessandro Cellini, Mark Catherwood, Sophia Chatzileontiadou, Caterina Chessa, Carlos Chiattone, Rosa Collado, Marta Coscia, Marta Crespo, Antonio Cuneo, Zadie Davis, Maria Dimou, Michael Doubek, Maria Efstathopoulou, Blanca Espinet, Gianluca Gaidano, Rocio Garcia-Serra, Alessandro Gozzetti, Ritu Gupta, Eleftheria Hatzimichael, Yair Herishanu, Ozren Jaksic, Maria Kislova, Eliana Konstantinou, Sevasti Konstantinou, Maya Koren Michowitz, Ioannis Kotsianidis, Andreas Epameinondas Koumpis, Luca Laurenti, Alexandros Machairas, Francesca Martini, Riccardo Moia, Samir Mouhssine, Ana Muntanola Prat, Roberta Murru, Rocio Nieves Salgado Sanchez, Gerassimos Pangalis, Maria Papaioannou, Sarka Pavlova, Leila Perobelli, Sarka Pospisilova, Anna Puiggros, Claus Rainer, Sergio Ramos, Lata Rani, Gian Matteo Rigolin, Ilaria Romano, Davide Rossi, Rodrigo Santucci, Angel Serna, Marina Siakantaris, Talita Silveira, Paolo Sportoletti, Niki Stavrogianni, Annamaria Tomasso, Kristina Tomic Vujovic, Livio Trentin, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Munci Yagci, Seyma Yildiz, Anastasia Chatzidimitriou, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2025) 146 (Supplement 1): 5664.

https://doi.org/10.1182/blood-2025-5664

Published: 2025

Journal Articles

Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience

Blood (2024) 144 (Supplement 1): 6798.

https://doi.org/10.1182/blood-2024-203557

Published: 2024

Journal Articles

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Enrica Antonia Martino, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Andrea Visentin, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Annamaria Frustaci, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Gerardo Musuraca, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Ernesto Vigna, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Ludovico Fraticelli, Candida Vitale, Azzurra Anna Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozzella, Luigi Malandruccolo, Enrico Derenzini, Valentina di Martina, Roberto Marasca, Maria Ilaria Del Principe, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Antonino Neri, Pellegrino Musto, Francesco Di Raimondo, Alessandra Tedeschi, Livio Trentin, Gianluca Gaidano, Fortunato Morabito, Valter Gattei, Massimo Gentile

Blood (2024) 144 (Supplement 1): 6794.

https://doi.org/10.1182/blood-2024-205354

Published: 2024

Journal Articles

Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation

Blood (2024) 144 (Supplement 1): 762.

https://doi.org/10.1182/blood-2024-194469

Published: 2024

Journal Articles

Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 1854.

https://doi.org/10.1182/blood-2024-203053

Published: 2024

Journal Articles

Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study

Blood (2024) 144 (Supplement 1): 4621.

https://doi.org/10.1182/blood-2024-205215

Published: 2024

Journal Articles

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

T C, Eva Minga, Georgios Karakatsoulis, Elisa Albi, Miguel Alcoceba, David Allsup, Francesca Bacchiarri, Sotiria Besikli-Dimou, Sofia Chatzileontiadou, Rosa Collado, Zadie Davis, Maria Dimou, David Donaldson, Maria Efstathopoulou, Sara Galimberti, Andrea Galitzia, Eva Gimeno, Valerio Guarente, Eleftheria Hatzimichael, Jose-Angel Hernandez-Rivas, Gloria Iacoboni, Iliana Konstantinou, Ioannis Kotsianidis, Jana Kotaskova, Andreas Epameinondas Koumpis, Zuzana Kubova, Jorge Labrador, Luca Laurenti, Juan Marquet, Stanislava Maslejova, Carlota Mayor-Bastida, Fatima Miras, Riccardo Moia, Almudena Navarro-Bailon, Jacopo Olivieri, Maria Papaioannou, Anna Puiggros, Gian Matteo Rigolin, Mattia Schipani, Tereza Shokralla, Martin Simkovic, Antigoni Tranidou, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Renata Walewska, Lucrecia Yanez San Segundo, Jana Zuchnicka, David Graham Oscier, Alessandro Gozzetti, Panayiotis Panayiotidis, Francesc Bosch, Paolo Sportoletti, Blanca Espinet, Gerassimos Pangalis, Maria Angelopoulou, Tomas Papajik, Roberta Murru, Marta Coscia, Antonio Cuneo, Gianluca Gaidano, Niki Stavrogianni, Livio Trentin, Lukas Smolej, Mark Caterwood, Martin Spacek, Sarka Pospisilova, Michael Doubek, Anastasia Chatzidimitriou, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2024) 144 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2024-202046

Published: 2024

Journal Articles

Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study

Blood (2023) 142 (Supplement 1): 6529.

https://doi.org/10.1182/blood-2023-181037

Published: 2023

Journal Articles

Impact of COVID-19 in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Possible Role of the Association to Anti-CD20 Antibody? a Multicentre Seifem Study

Blood (2023) 142 (Supplement 1): 3283.

https://doi.org/10.1182/blood-2023-180955

Published: 2023

Journal Articles

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Blood (2023) 142 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2023-174897

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Dissecting the heterogeneity of IGHV-mutated CLL: An eric study.

Targeting a novel surface antigen, ryk, with the antibody-drug conjugate, slv-404, is effective in richter transformation patient-derived xenografts

Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki

Brentuximab vedotin (Bv)+AVD efficacy is influenced by interim PET, age, ECOG performance status and CIRS-g in previously untreated patients with stage IV classical Hodgkin lymphoma: An Italian real-life multicentric study

Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study

Chronic obstructive pulmonary disease and prior pneumonia as predictors of infectious risk in chronic lymphocytic leukemia patients receiving acalabrutinib or zanubrutinib: A seifem multicentre Study.

Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.

Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by eric.

Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.

Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation

Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia

Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study

Impact of COVID-19 in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Possible Role of the Association to Anti-CD20 Antibody? a Multicentre Seifem Study

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only